Molecular Biologist by training (Ph.D. 1972 from the University of Chicago), David has been actively engaged in biotech start-ups and business development since 1998, when he participated in the founding of UroGene S.A. in Evry. While at UroGene he negotiated the contracts, e.g. with the Sanofi-Synthelabo pharmaceutical laboratories, that brought the company its first investors and an evaluation of over 20 million euros by 2000. Since leaving UroGene in 2001 he has applied his expertise to advise start-ups to retarget their business, in order to assure early benefits. His consulting activity, titled RxLS (an acronym that is an inversion of Ruben Solal, the youngest of four kids), has recently been concentrating on introducing medical devices into the marketplace. A network of friends and colleagues both in Europe and North America has strongly supported those efforts.

Using his expertise in genomics as well as immunology, David has also assisted basic research groups in tech transfer, an activity he began while at CEPH (Centre for Studies on Human Polymorphism – one of the first Human Genome Projects) from 1990 to 1994, and continued at Institut Pasteur (Paris) from 1996 to 1998, when some of the first biotechs were spinning out of Pasteur. At the same time he has continued to publish, specifically a series of articles and two monographs entitled Genomics (1996) and Pharmacogenomics (2002) both published by PJB, the editor of SCRIP, read by pharmaceutical and biotech executive